Patheon terminates manufacturing agreement with AcelRx; effective May 31, 2024

TALPHERA, INC.

Patheon provided notice on Nov 29, 2022 to terminate the MSA, originally dated Dec 12, 2012.
MSA termination effective May 31, 2024; Patheon to continue supplying product until then.
Capital Equipment Agreement between parties likewise terminates upon MSA termination.
AcelRx expects to discuss a transition plan with Patheon in the near future.

item 1.02 item 1.01

Key facts

Extracted from this filing and checked against the source text.

Material Agreements SEC 8-K Item 1.01/1.02 confidence 0.9

TALPHERA, INC. terminated MSA with Patheon Pharmaceuticals Inc. (effective 2024-05-31).

Action: termination
Agreement: supply
Counterparty: Patheon Pharmaceuticals Inc.
Effective: 2024-05-31

Exact text from the filing

On November 29, 2022, AcelRx Pharmaceuticals, Inc., a Delaware corporation (the “Company”), received notice from Patheon Pharmaceuticals Inc. (“Patheon”) that it intends to terminate the Manufacturing Services Agreement between the parties, effective December 12, 2012, as amended January 19, 2016 and August 4, 2017 (collectively, the “MSA”).

View on SEC.gov

38 material agreements filed in the last 30 days. Browse all material agreements →

TALPHERA, INC. filing history →

Source: SEC EDGAR

accession 0001437749-22-028437

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.